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Abstract 22	
Background: Allergic diseases have seen a rise worldwide with children 23	
suffering the highest burden. Thus early prevention of allergic diseases is a 24	
public health priority.  25	
Objective: To synthesise the evidence from randomised controlled trials 26	
(RCTs) assessing the efficacy of vitamin interventions during pregnancy on 27	
developing allergic diseases in offspring.  28	
Methods: We searched CENTRAL, MEDLINE, SCOPUS, WHO’s Int. Clin. 29	
Trials Reg., E-theses and Web of Science. Study quality was evaluated using 30	
the Cochrane’s risk of bias tool. Included RCTs had a minimum of 1-month 31	
follow-up post gestation. 32	
Results: A total of five RCTs met the inclusion criteria, including 2456 33	
children that used vitamins C+E (one study), vitamin C (one study) and 34	
vitamin D (three studies) compared with placebo/control. Two studies were 35	
judged to have a high risk of bias for performance bias or high rate of loss to 36	
follow-up. All were rated as low risk of bias for blinding of outcome 37	
assessment. We did not perform meta-analysis with vitamin C or C+E studies 38	
due to high heterogeneity between the two included studies. However we did 39	
conduct a meta-analysis with trials on vitamin D (including 1493 children) and 40	
the results showed an association between prenatal intake of vitamin D and 41	
the risk of developing recurrent wheeze in offspring (RR=0.812, 95 % 42	
CI=0.67-0.98).  43	
Conclusion: The current evidence suggests that prenatal supplementation of 44	
vitamin D, might have a beneficial effect on recurrent wheezing in children. 45	
Longer-term follow-up of these studies are needed to ascertain whether this 46	
observed effect is a sustained. There is lack of evidence on the effect of other 47	
vitamins for prevention of respiratory and/or allergic outcomes.  48	
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• What is already known about this topic? 
Few observational studies suggest that vitamin deficiency is associated 
with developing higher prevalence of allergic diseases in children; 
however we need robust evidence from randomised controlled trials to 
determine if this is the case. 
• What does this article add to our knowledge? 
This systematic review indicates that prenatal intake of vitamin D may 
protect against development of recurrent childhood wheeze. As early 
childhood wheeze is not necessarily the same as asthma, longer-term 
follow-ups of these trials are required to establish the efficacy of vitamin 
D in prevention of actual asthma in later childhood.  
• How does this study impact current management guidelines? 
Consumption of higher doses of vitamin D during pregnancy needs to be 
considered in pregnancy management policies. However the effective 
dose could vary depending on the baseline level of vitamin-D in different 
regions. 
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Introduction 65	
In the last two decades allergic diseases have seen a rise worldwide with 66	
children suffering the highest burden of the condition1. Food allergies, eczema 67	
and asthma are the most common allergic disorders in children1-2. Due to the 68	
increasing burden of allergic diseases they are a key focus for public health. 69	
 70	
The Developmental Origins of Health and Disease theory proposes that 71	
development is not dictated by a hard-wired genetic programme, instead the 72	
organism responds to the surrounding environment and the risk of many 73	
diseases is set during this time3. It has become increasingly evident that there 74	
is an important role for environmental factors in the onset of complex 75	
conditions such as allergic diseases and that the role of fixed genetic variation 76	
is far less than previously believed4. Therefore, new approaches towards 77	
disease prevention with an emphasis on early interventions i.e. pre-pregnancy 78	
and/or during pregnancy need to be widely investigated. Current evidence 79	
suggests that the role of maternal diet during pregnancy on subsequent 80	
disease development is a priority area for future studies5, as many of the 81	
immune modulatory processes may start in-utero. 82	
 83	
The role of environmental and life-style factors on developing allergies has 84	
been examined in a number of epidemiological studies. A systematic review 85	
has investigated the association of nutrient deficiencies on the risk of 86	
development of asthma and allergic diseases in children6. This review 87	
included 62 observational studies and indicated that vitamins A, D, and E; 88	
zinc; fruits and vegetables; and a Mediterranean diet during pregnancy may 89	
prevent asthma and wheeze. However, this review was based on 90	
observational studies which carry a high risk of bias and there is a need for 91	
secondary research based on summary of more robust interventional studies.  92	
 93	
The purpose of this systematic review was to summarise the existing 94	
evidence form randomised controlled trials for the association between 95	
vitamin supplements during pregnancy and the risk of developing allergic 96	
disorders in the offspring.  97	
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Methods 98	
Criteria for considering studies for this review 99	
Types of studies 100	
Only randomised controlled trials (RCT) (including cluster randomised 101	
controlled trials and quasi-randomised controlled trials) with a minimum 102	
follow-up of one month postnatally were included. The review considered 103	
studies which documented clinical outcome data and used any types of 104	
vitamins. No language restriction was applied.  105	
Types of participants 106	
Pregnant women and their offspring, regardless of their location were 107	
considered as the target group for this systematic review. High risk 108	
populations were not excluded. 109	
Types of interventions 110	
Studies that used any vitamin supplementation during pregnancy, irrespective 111	
of dose, formulation or mode of delivery and composition e.g. oil, tablet.    112	
Trials were also included if the intervention(s) had been extended after 113	
pregnancy either during breast-feeding or with the infants or both.  114	
Outcomes of interest 115	
Trials were included if they had reported clinical outcomes of allergy in the 116	
offspring, either as a primary or secondary endpoint. Allergic outcomes were 117	
defined as: asthma, wheeze, rhinitis, eczema, food allergy and positive skin 118	
prick test (to any allergen) and elevated specific IgE. Outcomes included were 119	
those, which had utilised a validated method as opposed to parental reports. 120	
Search strategy for identification of studies 121	
A comprehensive search strategy, including all the relevant synonyms for the 122	
main concepts, was developed covering the main bibliographic databases 123	
(online repository). Trials were identified through systematic searches within 124	
three main electronic databases, as advised by the Cochrane collaboration7: 125	
a. Cochrane Library (current issue) including: 126	
• Cochrane Database of Systematic Reviews (CDSR)  127	
• CENTRAL (trials) 128	
• DARE 129	
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b. MEDLINE (EBSCOhost)  130	
c. SCOPUS 131	
When searching MEDLINE, the subject-specific terms were combined with the 132	
Cochrane Highly Sensitive Search Strategy for identifying randomised trials in 133	
MEDLINE: sensitivity-maximising version7. We adapted the preliminary 134	
search strategy for MEDLINE (EBSCOhost) for use in the other databases 135	
when relevant. The last search for literature was conducted in January 2016.  136	
The clinical trials registry and WHO platform were searched for ongoing and 137	
recently completed trials. Conference proceedings were identified through the 138	
ISI Web of Science and, for retrieving theses the British Library E-Theses 139	
Online Service was searched. No language or publication status restrictions 140	
were imposed. References of included studies were crosschecked for 141	
additional studies.   142	
Data collection and analysis 143	
Selection of studies 144	
The main reviewer (MV) screened all the search results against the eligibility 145	
criteria and all those which were clearly irrelevant were excluded from further 146	
consideration. Thereafter, a tailored eligibility form was used by MV to 147	
appraise the retrieved studies, abstract and full text for relevance against the 148	
full inclusion criteria. Where there was uncertainty about inclusion of a 149	
particular study, other members of the review team (HM & TD) were consulted 150	
and a consensus was reached about the study eligibility. All the included 151	
studies were discussed and approved by the review team.  152	
Data extraction 153	
MV extracted the data using a tailored data extraction form (online repository). 154	
Detailed information on study characteristics were recorded. Throughout the 155	
data extraction process, any disagreements about the interventions and 156	
outcomes were discussed and resolved within the review team. There was no 157	
blinding to the name of authors, institutions, journals or the outcomes of the 158	
trials during the process. Ten percent of all the extracted data was randomly 159	
selected and double checked by a second reviewer (HM) for accuracy against 160	
the trial reports. 161	
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Assessment of risk of bias in included studies 162	
The risk of bias tool described in the Cochrane Handbook for Systematic 163	
Reviews for Interventions was used to appraise the studies8. The tool includes 164	
seven domains: random sequence generation, allocation concealment, 165	
blinding of participants and personnel, blinding of outcome assessments, 166	
incomplete outcome data, selective outcome reporting and other bias.  167	
Measurement of treatment effect 168	
Dichotomous data was analysed as risk ratios or relative risk (RR) with 95% 169	
CI and continuous data as mean difference or standardised mean difference, 170	
with 95% CI.  171	
Unit of analysis issues 172	
In trials with more than one intervention arm, multiple pairwise comparisons of 173	
intervention groups versus comparator were avoided. Therefore, data from 174	
different intervention arms were pooled for an overall comparison with the 175	
control or placebo arm. The weight assigned to the control group was 176	
considered as the total number of participants in the comparator group versus 177	
the total number of participants in the combined intervention arms9.  178	
Handling missing data 179	
All the relevant reported information for the number of missing participants 180	
was extracted and if undocumented, this was incorporated into the 181	
assessment of risk of bias. No imputed techniques were used for retrieving 182	
missing data.  183	
Assessment of heterogeneity 184	
We used visual inspection of forest plots and also, the Chi2 test to measure 185	
statistical heterogeneity between effect sizes of included studies (P<0.05)10. I2 186	
statistics were used to quantify the amount of possible variability in effect 187	
estimates that is due to heterogeneity rather than chance (I2 >30% moderate 188	
heterogeneity, I2 ≥75% considerable heterogeneity).  189	
Assessment of reporting biases 190	
Every effort was made to identify unpublished studies through searching 191	
abstracts and ongoing trials databases. Publication bias was assessed using 192	
funnel plots11. The asymmetry was assessed visually in the plots and no 193	
formal statistical tests were conducted. The funnel plot was helpful to explore 194	
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possible small study biases for some of the primary outcomes (online 195	
repository).  196	
Data synthesis  197	
We used Eppi Reviewer version 4.4.3.0. for conducting meta-analyses using 198	
random-effects model. Dichotomous data were entered as events and the 199	
number of participants. Data were pooled using random-effects model where 200	
heterogeneity was reported as ≤75%7. We also reported relative risk as a 201	
statistical choice in conducting the meta-analyses, as it is easy to interpret12.  202	
Subgroup analysis and investigation of heterogeneity  203	
We performed sub-group analyses based on the type of vitamin and type of 204	
the control group (i.e. placebo versus no treatment).  205	
Sensitivity analysis 206	
We did not conduct any sensitivity analysis because of the small number of 207	
studies that contributed to meta-analyses.  208	
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Results  209	
The results of the search strategy yielded 341 studies, of which 26 were 210	
selected for full-text assessment (Figure1). We included 5 RCTs comparing at 211	
least one vitamin with a control that met the inclusion criteria for this 212	
systematic review.  213	
 214	
These included trials (including total of 2456 children) were represented by 215	
five original papers13-17 and four grouped as their companion papers18-21. 216	
Table 1 shows the characteristics of the included trials, their companion 217	
papers and study population. The trials were conducted in United Kingdom, 218	
Denmark and United States. The types of vitamin supplementations included 219	
were as vitamins C+E13, vitamin D14,16-17 and crushed vitamin C15. The 220	
duration of intervention and follow-up in the included studies varied from 3.5-4 221	
to 7.5 months and 12 to 36 months respectively. In trials that used vitamins C 222	
and C+E, a higher blood concentration of vitamins was observed in those 223	
assigned antioxidants13&15. In trials that used vitamin D, level of maternal 25-224	
hydroxyvitamin D measured either at third trimester or after delivery and was 225	
significantly higher in the treatment versus comparison group14, 16&17. The 226	
most frequently reported outcomes were wheeze and eczema. As expected 227	
with systematic reviews there were differences between the included trials in 228	
terms of type of the population, supplementation used and the comparators. 229	
We have therefore described the results of individual studies narratively and 230	
only conducted meta-analysis when there was no evidence of statistical 231	
heterogeneity. The definition and diagnosis method of the outcomes in each 232	
study are presented in online repository. 233	
 234	
Vitamin C studies 235	
Greenough et al. (2010)13 study 236	
The study was conducted in the U.K between August 2003 to June 2007. The 237	
studied sample were pregnant women at risk of developing pre-eclampsia. 238	
Women were supplemented with daily vitamins C (1,000mg) tablets and E 239	
(400IU) gelatin capsules, from 16-22 gestation weeks until delivery. Women in 240	
the control group received identical tablets of microcrystalline cellulose with 241	
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addition of tartaric acid and citric acid along gelatin capsules of sunflower 242	
seed oil. Compliance with the intervention was measured by counts of 243	
returned pills. Primarily this study was designed to prevent the risk of fetal 244	
growth restriction and premature delivery in the women18 and the extended 245	
follow-up at 2 years has assessed the efficiency of the vitamin intervention on 246	
respiratory outcomes in children.  247	
 248	
The list of the reported outcomes in the study is shown in Table 1. The 249	
outcomes of “asthma” and “eczema” are reported at 1-year age and “recurrent 250	
wheeze” at 2 years. No statistically significant association was observed 251	
between the intervention and control group for prevention of recurrent wheeze 252	
(10/386 vs. 11/366, OR=0.83, 95% CI=0.26-2.59, p=0.66) and asthma 253	
(23/386 vs. 23/366, OR=0.94, 95% CI=0.42-2.11, p=0.85). Additionally the 254	
results did not show a significant association between prenatal intake of 255	
vitamin C+E and prevention of eczema (98/386 vs. 86/366, OR=1.10, 95% 256	
CI=0.70-1.74, p=0.58). 257	
 258	
McEvoy et al. (2014)15 study 259	
The study was conducted in U.S.A between March 2007 and January 2011. 260	
The studied sample were smoking pregnant women. Women were 261	
supplemented with daily crushed vitamin C (500mg) gel capsules, from 22nd 262	
gestation weeks until delivery. Women in the control group received ground 263	
cornstarch in gel capsules. Adherence was measured by dividing the number 264	
of capsules taken by the total number prescribed in a given period.    265	
 266	
The study reported the efficiency of consumption of vitamin C during 267	
pregnancy on pulmonary function tests and wheezing in children at 1-year 268	
age. The list of the reported outcomes in the study is shown in Table 1. The 269	
results of the unadjusted analysis showed no significant statistical association 270	
between the intervention and control groups for outcome measure defined as 271	
“recurrent wheeze” (9/76 vs. 17/83, RR=0.56, 95% CI=0.27-1.18, p=0.13). A 272	
significant difference was observed for the outcome of “at least 1 episode of 273	
wheezing” between the intervention and control groups (15/76 vs. 31/83, 274	
RR=0.56, 95% CI=0.33-0.95, p=0.03). 275	
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Given the fact that there is high heterogeneity between the studies that 276	
supplemented pregnant women prenatally with vitamin C, we did not perform 277	
meta-analysis for these trials.  278	
 279	
Vitamin D studies  280	
Goldring et al. (2013)14 study 281	
The study was conducted in the U.K between April and November 2007. This 282	
study recruited pregnant women with multiple ethnicities. The study 283	
introduced two intervention arms, as women were randomised either to 284	
receive a daily dose of ergocalciferol (800IU) or a single oral dose of 285	
cholecalciferol (200,000IU, bolus), from 27 gestation weeks until delivery. The 286	
comparator in this study was defined as “no treatment”. Adherence was 287	
measured by telephone calls during pregnancy.  288	
 289	
This study followed up children to up 3 years of age and this systematic 290	
review only reports the results for the intervention arm of daily vitamin D. The 291	
results of unadjusted analysis for “recurrent wheezing” showed no statistical 292	
significant association between prenatal intake of daily vitamin D and control 293	
group (8/56 vs. 7/50, RR=1.02, 95% CI=0.40-2.61, p=0.97). Furthermore, no 294	
significant association was observed for the outcome measure of “wheeze 295	
with positive asthma predictive index” (6/56 vs. 7/50, RR=0.77, 95% CI=0.28-296	
2.13, p=0.61) between the study arms. The outcomes of “eczema in the last 297	
year” (11/55 vs. 7/49, RR=1.40, 95% CI=0.59-3.33, p=0.44) and “food allergy 298	
diagnosis” (8/55 vs. 3/49, RR=2.38, 95% CI=0.67-8.46, p=0.16) did not show 299	
a significant statistical association for the prenatal consumption of daily 300	
vitamin D in comparison to control.  301	
 302	
Chawes et al. (2016)16 study 303	
The study was conducted in Denmark between 2008 to 2010. The studied 304	
sample were unselected pregnant women. Women were supplemented with 305	
daily vitamin D3 (2,400IU) tablets, from 24 gestation weeks to one week after 306	
delivery. Women in the control arm received tablets containing no active 307	
substance. In addition, women assigned to both intervention and control arms 308	
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received an extra 400IU dose of vitamin D3, as part of their routine care. 309	
Compliance to the intervention was measured by counts of returned pills.  310	
 311	
The study reported cumulative incidence of the allergic outcomes by 3 years 312	
of age. The results of unadjusted analysis indicated that the risk of developing 313	
recurrent wheeze did not show a significant difference between the 314	
intervention and control group (47/295 vs. 57/286, HR=0.76, 95% CI=0.52-315	
1.12, p=0.16). Asthma was reported at 3 years of age only and no significant 316	
difference was observed between the intervention and control groups (32/278 317	
vs. 47/271, OR=0.82, 95% CI=0.50-1.36, p=0.45). Furthermore there was not 318	
a significant statistical difference between the study arms for eczema as an 319	
outcome (68/295 vs. 72/286, HR=0.90, 95% CI=0.65-1.26, p=0.55). Children 320	
in the intervention arm reported statistically significant “lower episodes of 321	
troublesome lung symptoms” compared to the control group (5.9 vs. 7.2, 322	
IRR=0.83, 95% CI=0.71-0.97, p=0.02). The cumulative results for SPT and 323	
sIgE outcomes were not statistically different between the intervention and 324	
control group (24/294 vs. 19/283, OR=1.24, 95% CI=0.66-2.31, p=0.51) and 325	
(34/289 vs. 22/278, OR=1.55, 95% CI=0.89-2.73, p=0.13) respectively.  326	
 327	
Litonjua et al. (2016)17 study 328	
The study was conducted in U.S.A between 2009 to 2011. The study sample 329	
were women with a history of atopy. Women were supplemented with daily 330	
vitamin D3 (4,000IU) tablets, between 10-18 gestation weeks until delivery. 331	
The nature of the placebo capsules was not reported. Women in both study 332	
arms also received a multivitamin with 400IU of vitamin D. Adherence to the 333	
intervention was measured by electronic medication container caps. 334	
 335	
The study reported cumulative incidence of the allergic outcomes by 3 years 336	
of age. The outcomes of “asthma or recurrent wheeze” were reported together 337	
and the results showed no significant statistical difference between the 338	
intervention and control groups (98/405 vs. 120/401, HR=0.8, 95% CI=0.6-339	
1.0, p=0.051). There was also no significant statistical difference in the risk of 340	
developing “eczema with rash” in the study arms (83/405 vs. 89/401, HR=0.9, 341	
95% CI=0.7-1.2, p=0.56). The result for positive sIgE tests at 3 years showed 342	
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a significant statistical difference between the intervention and control group 343	
(43/405 vs. 50/401, MD=-1.7, 95% CI=-3.4-0.0, p=0.02). 344	
 345	
Meta-analyses of vitamin D studies 346	
We conducted a meta-analysis for the outcome measure of “recurrent 347	
wheeze” for trials that used vitamin D prenatally in pregnant women. Figure 2 348	
shows the Forest plot for this outcome. Three trials contributed to the meta-349	
analysis including a total of 1,493 children. No statistical heterogeneity was 350	
observed between the included trials (Chi2=0.16, p=0.92, I2=0%) (Figure 2). 351	
The results of the present meta-analysis showed an association between 352	
maternal intake of daily vitamin D during pregnancy and a lower risk of 353	
developing recurrent wheeze in offspring (RR=0.812, 95% CI=0.673-0.98). 354	
We also conducted the meta-analysis including only the two recent vitamin D 355	
trials16&17 and it yielded similar results (Forest plot not shown). 356	
 357	
Risk of bias in included trials 358	
The risk of bias figures and authors’ judgments are presented in online 359	
repository. Only one trial was deemed to have low risk of bias across all 360	
domains17. Of the 5 trials, most had adequate random sequence generation 361	
(n=3), allocation concealment (n=3) and performance bias (n=3). All trials 362	
were rated as having a low risk of bias for blinding of outcome assessment 363	
and selective outcome reporting. Completeness of outcome data was rated as 364	
having high risk of bias for one trial13 since the study had a high loss to follow-365	
up and the authors acknowledged the fact that the study was an unplanned 366	
extended follow-up of the original trial for measuring allergic outcomes in 367	
children. The original trial was primarily designed to assess the efficacy of 368	
vitamins C and E supplementation on developing pre-eclampsia in women at 369	
increased risk.  370	
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Discussion 371	
This is the first systematic review of randomised controlled trials that 372	
investigated the association of prenatal intake of vitamins on the risk of 373	
developing allergic/respiratory diseases in the offspring. We identified five 374	
RCTs with a total of 2456 children. The studies were of unselected pregnant 375	
women16, women with a history of atopy17, pregnant women at risk of 376	
developing pre-eclampsia13, different ethnic/race groups14 and smoking 377	
pregnant women15. Two studies were judged to have a high risk of bias due to 378	
their performance bias13-14 or high rate of loss to follow-up13. All trials were 379	
rated having low risk of bias for blinding of outcome assessment. It was not 380	
possible to conduct meta-analyses for vitamin C studies due to observed 381	
differences between the included trials. Maternal vitamin D consumption 382	
during pregnancy was associated with a lower risk of developing recurrent 383	
wheeze in offspring, when compared to placebo/control. However we were 384	
not able to investigate the efficiency of vitamin D on other allergic outcomes 385	
since outcomes were reported differently in the included trials. In all trials, 386	
supplementation with vitamins significantly increased the concentration of 387	
vitamins in the intervention group compared to the control group by the end of 388	
the intervention.  389	
 390	
Observational studies typically report a beneficial effect of higher intake of 391	
vitamin D as well as antioxidants during pregnancy on allergic outcomes22-23. 392	
The results from this systematic review proposed a protective effect of 393	
prenatal intake of vitamin D during pregnancy for prevention of recurrent 394	
wheeze in offspring. However we could not address the effect of prenatal 395	
intake of vitamin C or D on other allergic outcomes owing to the observed 396	
heterogeneity between the trials.  397	
 398	
It is possible that the follow-up periods of the studies for this review have been 399	
too short to detect other allergic outcomes i.e. asthma. For example, 400	
wheezing is known as a primary symptom of asthma in early childhood24 and 401	
about 40% of childhood wheeze will persist later in life and will eventually 402	
develop into asthma by 6 years of age25-26, indicating majority of wheeze 403	
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during infancy are in fact acute respiratory infection. Therefore, extended 404	
follow-up of these trials could help to provide a clearer answer as to whether 405	
the vitamin D intervention is beneficial for asthma prevention. 406	
  407	
There were also some limitations in the studies’ design. For example, the 408	
trials were statistically underpowered to detect an effect for their primary 409	
and/or secondary outcome measures. Significant differences were only 410	
observed for some of the secondary outcomes as “at least 1 episode of 411	
wheezing”14, “episodes of troublesome lung symptoms”16 and “positive sIgE”17 412	
and trials failed to show a beneficial effect for primary allergic outcomes such 413	
as wheeze and asthma in children. Also, the trials used different doses of 414	
vitamins during pregnancy. The dose of vitamin D varied between 800-4000IU 415	
and doses of vitamin C and/or E, varied between 500-1000mg. It is possible 416	
to hypothesis that lower doses of vitamins may have failed to reach the 417	
desirable level of 25-hydroxyvitamin D or antioxidants in pregnant women to 418	
have an influential effect on the fetal immune programming and lung 419	
function27-29. However this is refuted by studies which have reported similar 420	
effect size using higher doses of vitamin D16&17. A previous RCT by 421	
addressing the safety and efficacy of vitamin D supplementation during 422	
pregnancy showed that a 4000IU vitamin D is a safe approach and was 423	
necessary to optimise the circulating concentration of 25-hydroxyvitamin D 424	
levels to ≥ 80nmol/L30. There is limited evidence on the safety of vitamins C 425	
and E intake at any stage of pregnancy; however the Institute of Medicine’s 426	
Food and Nutrition Board have set an upper limit of 2000mg and 1000mg per 427	
day for vitamins C and E ingestion respectively during pregnancy in the 428	
United States31.  429	
 430	
Further, in all trials the intervention was started in the 2nd trimester in 431	
pregnancy. However the development of the lungs begins in the first trimester 432	
in pregnancy and vitamin D plays an immunomodulatory role in the 433	
development of lung and immune system32. Therefore the interventions might 434	
have commenced too late in pregnancy or some used too low dose of vitamin 435	
D to have a beneficial impact on lung development. Finally, the studies 436	
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recruited different types of population, which limits the generalisability of the 437	
studies. Baseline levels of vitamin D vary in different geographical areas33 and 438	
this issue has not been addressed in the conducted trials. Well-designed trials 439	
are necessary to address all these possible confounders among different 440	
populations34. Further larger scale research should administer vitamin D 441	
earlier in pregnancy or pre-pregnancy and employs appropriate doses of 442	
vitamin D to achieve a desirable level of vitamin D in maternal and fetal blood. 443	
Furthermore, studies assessing the efficiency of nutrients are required to 444	
consider the defined guidelines in their clinical design enabling to test the 445	
associated hypothesis in a valid manner35.    446	
 447	
To date, no other systematic review has evaluated the efficacy of prenatal 448	
vitamins on the prevention of allergic and/or respiratory outcomes in children. 449	
The result from the current evidence is promising that prenatal intake of 450	
vitamin D could protect childhood wheeze. The role of maternal consumption 451	
of vitamins during pregnancy on the risk of developing other allergic outcomes 452	
and sensitisation needs to be investigated in larger well-designed trials. 453	
Further it will be important for future research to examine the impact of the 454	
timing of the intervention and the optimum dose of vitamins. We were unable 455	
to perform any meta-analyses on the timing or dose of intervention and study 456	
populations due to the small number of trials that could contribute to meta-457	
analyses.  458	
 459	
The current evidence suggests that prenatal intake of daily vitamin D might 460	
protect against recurrent childhood wheeze; however there is currently lack of 461	
evidence that prenatal intake of vitamins can prevent any other 462	
allergic/respiratory outcomes. 463	
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Figure 1: Study flow diagram, following PRISMA criteria 
Records identified through database 
searches (n=340) 
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Measure: Binary: risk ratio 
Heterogeneity: Q = 0.163; df = 2; p = 0.922; I-squared = 0%; tau-squared = 0 
Random effects model: 0.812 (0.673, 0.98) 
 
		
Outcome	 Vitamin	D	 Placebo	 Participants	 Study	sample	
Wheeze-Daily	
Vitamin	D	vs.	
Placebo	or	no	
treatment	
n/N	 n/N	 	 	
Goldring2013	 7/50	 8/56	 	 Unselected		Chawes	2016	 47/295	 57/286	 	 Unselected		Litonjua	2016	 98/405	 120/401	 	 Atopic		
Subtotal	 750	 743	 1493	 	
 
Figure 2: Forest plot for daily vitamin D intake vs. placebo or no 
treatment as the control for prevention of recurrent wheeze in offspring 
 
